Multiple Primaries will be run sequentially. See reverse side for details.

1) Genomic Health to request specimen from Pathology
2) Ordering Physician to request specimen from Pathology

Specimen ID(s) Only one specimen is typically required. The Oncotype DX assay will be completed on the specimens in the order listed below. For multiple primaries, list the most aggressive tumor first.

1) __________________________

2) __________________________

Date of Collection __________________________ (MM/DD/YYYY)

Date Block Pulled from Archive __________________________ (Medicare Only)

Specimen Comments

Specimen Barcode

Affix Specimen barcode here
REQUISITION FORM INSTRUCTIONS

Online ordering is available at online.genomichealth.com. For assistance in setting up a Portal Account for online ordering, please contact Customer Service at 866-ONCOTYPE or customerservice@genomichealth.com.

STUDY INFORMATION
1. If the order is associated with a Genomic Health involved study, enter the applicable study code.

TEST & CLINICAL INFORMATION
1. Select the requested test and enter clinical information where required.
   a. Invasive Breast Cancer patients
      i. Ensure the ER status and nodal status are accurate, as this information informs the report results.
   1. A specimen submitted for the Oncotype DX Breast Recurrence Score® Test must be estrogen receptor positive (ER+) by either the IHC method used by a referring laboratory or the quantitative RT-PCR method used by GHI. If GHI determines that the submitted specimen is not ER+ by either method, a result will not be reported and the fees paid will be billed. The specimen is assumed to be ER+ if no selection is made.
   2. The nodal status is required to determine the extent of the clinical experience information to be included in the report for your patient. If the nodal status is not provided, a report with clinical experience information for both node negative and node positive specimens will be sent.
      ii. Result reports will include ER, PR, and HER2 scores.
   b. Ductal Carcinoma In Situ patients (no invasive breast cancer present)
      i. Result reports will include ER and PR scores.
   c. Colon Cancer patients
      i. The use of the test in clinical stage II MMR-Deficient or in clinical stage III C patients has limited clinical applicability.
      ii. In some cases, Genomic Health may use additional assessment methods, including confirmatory testing for HER2 status, to verify that the specimen meets the criteria for the Oncotype DX test.
      iii. Clinical information may be required for payor coverage determinations. If it is not provided, GHI may use the pathology report to obtain this information for reimbursement purposes.

PHYSICIAN INFORMATION
1. Enter the contact information for the Ordering Physician. You may also enter the contact information for another healthcare provider who is treating the patient and should receive a copy of the report.
2. Assay results will be delivered to the Ordering Physician and additional recipients via the secure online portal and/or by fax based on the physicians’ report delivery preferences on file at Genomic Health. To establish or change report delivery preferences, please contact Customer Service.

PHYSICIAN SIGNATURE & ATTESTATION
1. The signature must be of an Ordering Physician (treating physician or pathologist) or his/her authorized delegate. Stamped signatures are not acceptable. If this order form is completed by the Physician’s representative, the patient’s medical record must contain the signed order from the Ordering Physician.
2. If the Requisition Form attestation has been signed and no exception criteria must contain the signed order from the Ordering Physician.
   a. Colon Cancer patients
      i. The use of the test in clinical stage II MMR-Deficient or in clinical stage III C patients has limited clinical applicability.
      ii. In some cases, Genomic Health may use additional assessment methods, including confirmatory testing for HER2 status, to verify that the specimen meets the criteria for the Oncotype DX test.
   b. Ductal Carcinoma In Situ patients (no invasive breast cancer present)
      i. Result reports will include ER and PR scores.
   c. Invasive Breast Cancer patients
      i. Ensure the ER status and nodal status are accurate, as this information informs the report results.

PATHOLOGY & SPECIMEN INFORMATION
1. Enter the identification number for the most representative specimen (i.e. the longest linear length of the highest grade tumor) on the appropriate line.
2. If multiple primaries are being submitted, enter the most aggressive tumor on line one; it will be processed first.
3. While the GHI laboratory can accept tumor blocks and unstained slides, blocks are preferred.
4. Include a copy of the pathology report corresponding with the sample planned for evaluation with the Specimen Kit submission box. The pathology report may be used for reimbursement and/or administrative purposes.
5. If more than one tumor is being submitted for the patient, each tumor must be labeled with a unique Specimen Barcode (S-Barcode). GHI is not responsible for selecting the order in which specimens will be run. GHI will use the specimens in the order listed to complete the test.

SPECIMEN PREPARATION INSTRUCTIONS
1. For specimen criteria and specimen preparation instructions, visit oncotypeiq.com.
2. Please send either:
   • One fixed paraffin embedded tumor block.
   • Fifteen 5 µm serial unstained slides.
   • Important: Hand number the serially sectioned slides to indicate the order in which they were cut. Unnumbered slides will be returned.
   • Formalin is the preferred fixative. Tissues processed in other fixatives should not be submitted.
   4. Label all specimens with barcode labels from the Specimen Collection and Transportation Kit. Affix a coinciding barcode in the designated area on the Order Form. (Discard any remaining barcodes; do not use for future submissions.)
5. Label the specimen with an additional patient-specific identifier (e.g. patient name, date of birth, hospital number, order number, accession number).

DOMESTIC SHIPPING INSTRUCTIONS
1. Before shipping, make a copy of the Order Form and Statement of Medical Necessity and retain it for your records.
2. Place the Oncotype DX Specimen Kit into the FedEx® Clinical Pak.
3. Complete the FedEx US Airbill. The airbill is pre-printed with Genomic Health shipping information.
4. Seal the Clinical Pak by removing the plastic adhesive protector from the white strip and secure.
5. Place the package in the designated FedEx pickup location at your site.
6. If your site does not have standard FedEx pickup, call 800-GO FEDEX (800-463-3339) to arrange for pick up.
7. To order additional kits, email Customer Service at customerservice@genomichealth.com.